Skip to main content
Top
Published in: Annals of Hematology 11/2012

01-11-2012 | Original Article

The use of adjusted ideal body weight for overweight patients undergoing HPC mobilisation for autologous transplantation

Authors: C. Hicks, A. Trickett, Y. L. Kwan, S. Ramanathan

Published in: Annals of Hematology | Issue 11/2012

Login to get access

Abstract

Generally, patients’ actual body weight (ABW) is used to calculate the number of CD34+ cells to be harvested for autologous haematopoietic progenitor cell (HPC) transplantation. In our institution, ‘overweight’ patients weighing at least 25 % more than their ideal body weight (IBW) have their adjusted ideal body weight (AdjIBW) used for determination of blood volume to be processed to achieve a minimum target of CD34+ cells per kilogram, as well as CD34+ cell dosage calculation at transplant. AdjIBW is calculated as follows: AdjIBW = IBW + 0.25 × (actual weight − IBW). We have used AdjIBW for 65/153 patients who have had autologous HPC harvests, with a median AdjIBW of 69 kg (range, 50–110 kg). Median actual weight was 90 kg (range, 62–175 kg). Median volume of peripheral blood processed to achieve a minimum 2 × 106 CD34+ cells/kg for these patients was 13.2 L (range, 5–35 L), and the median CD34+ cells × 106/kg collected for AdjIBW was 6.3 (range, 1.7–33). For normal-weight patients (n = 88; median ABW, 75 kg; range, 49–98 kg), the corresponding median apheresis volume was 16 L (range, 7–24 L), and median CD34+ cells × 106/kg harvested was 4.5 (range, 1.4–15.9). In total, 35 in a total transplant cohort of 82 patients had AdjIBW used to determine CD34+ cell dose at time of transplant, with a median of 4.5 × 106/kg, (if their ABW was used in the calculation; 3.1 × 106/kg), compared to median dose of 3.2 × 106/kg ABW for the normal-weight patient cohort. All patients engrafted with no significant difference between median times to neutrophil and platelet engraftment for the overweight (13 and 15 days, respectively) compared with normal-weight (12 and 14 days, respectively) patient cohorts. We conclude that the use of AdjIBW is a useful tool for successful harvest and subsequent transplant for overweight patients, with no adverse effect on engraftment times.
Literature
1.
go back to reference Desikan KR, Tricot G, Munshi NC, Annaissie E, Spoon D, Fassas A et al (2001) Preceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocycte colony-stimulating factor alone. Br J Haematol 112:242–247PubMedCrossRef Desikan KR, Tricot G, Munshi NC, Annaissie E, Spoon D, Fassas A et al (2001) Preceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocycte colony-stimulating factor alone. Br J Haematol 112:242–247PubMedCrossRef
2.
go back to reference The ABMTRR Steering Committee of the BMTSANZ Australian Bone Marrow Transplant Recipient Registry (ABMTRR) Annual Data Summary 2008 The ABMTRR Steering Committee of the BMTSANZ Australian Bone Marrow Transplant Recipient Registry (ABMTRR) Annual Data Summary 2008
3.
go back to reference Pasquini MC, He V, Perez WS (2006) CIBMTR summary slides part 1. CIBMTR Newsletter 12:5–7 Pasquini MC, He V, Perez WS (2006) CIBMTR summary slides part 1. CIBMTR Newsletter 12:5–7
4.
go back to reference Bessinger W, Appelbaum F, Rowley S, Storb R, Sanders J, Lilleby K et al (1995) Factors that influence collection and engraftment of autologous peripheral blood-stem cells. J Clin Oncol 13:2547–2555 Bessinger W, Appelbaum F, Rowley S, Storb R, Sanders J, Lilleby K et al (1995) Factors that influence collection and engraftment of autologous peripheral blood-stem cells. J Clin Oncol 13:2547–2555
5.
go back to reference Singhal S, Gordon LI, Tallman MS, Winter JN, Evens AO, Frankfurt SF et al (2006) Ideal rather than actual body weight should be used to calculate cell dose in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 37:553–557PubMedCrossRef Singhal S, Gordon LI, Tallman MS, Winter JN, Evens AO, Frankfurt SF et al (2006) Ideal rather than actual body weight should be used to calculate cell dose in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 37:553–557PubMedCrossRef
6.
go back to reference Waples JM, Moreb JS, Sugrue M, Belanger G, Kubilis P, Lynch JW et al (1999) Comparison of autologous peripheral blood stem cell dosing by ideal vs actual body weight. Bone Marrow Transplant 23:867–873PubMedCrossRef Waples JM, Moreb JS, Sugrue M, Belanger G, Kubilis P, Lynch JW et al (1999) Comparison of autologous peripheral blood stem cell dosing by ideal vs actual body weight. Bone Marrow Transplant 23:867–873PubMedCrossRef
7.
go back to reference Ali MY, Oyama Y, Monreal JN, Winter JN, Tallman MS, Williams SF et al (2003) Ideal or actual body weight to calculate CD34+ cell doses for autologous hematopoietic stem cell transplantation? Bone Marrow Transplant 31:861–864PubMedCrossRef Ali MY, Oyama Y, Monreal JN, Winter JN, Tallman MS, Williams SF et al (2003) Ideal or actual body weight to calculate CD34+ cell doses for autologous hematopoietic stem cell transplantation? Bone Marrow Transplant 31:861–864PubMedCrossRef
8.
go back to reference Cilley J, Rihn C, Monreal J, Gordon LI, Singhal S, Tallman M et al (2004) Ideal or actual body weight to calculate CD34+ cell doses for allogeneic hematopoietic stem cell transplantation? Bone Marrow Transplant 33:161–164PubMedCrossRef Cilley J, Rihn C, Monreal J, Gordon LI, Singhal S, Tallman M et al (2004) Ideal or actual body weight to calculate CD34+ cell doses for allogeneic hematopoietic stem cell transplantation? Bone Marrow Transplant 33:161–164PubMedCrossRef
9.
go back to reference Flegal KM, Carroll MD, Ogden CL, Curtin LR (2010) Prevalence and trends in obesity among US adults, 1999–2008. JAMA 303:235–241PubMedCrossRef Flegal KM, Carroll MD, Ogden CL, Curtin LR (2010) Prevalence and trends in obesity among US adults, 1999–2008. JAMA 303:235–241PubMedCrossRef
10.
go back to reference Australian Bureau of Statistics 4364.0 National Health Survey: Summary of Results, 2007–08. Reissued 2009 Australian Bureau of Statistics 4364.0 National Health Survey: Summary of Results, 2007–08. Reissued 2009
11.
go back to reference Harousseau J-L, Moreau P (2009) Autologous hematopoietic stem-cell transplantation for multiple myeloma. N Engl J Med 360:2645–2654PubMedCrossRef Harousseau J-L, Moreau P (2009) Autologous hematopoietic stem-cell transplantation for multiple myeloma. N Engl J Med 360:2645–2654PubMedCrossRef
12.
go back to reference Gren B, Duffull SB (2004) What is the best size descriptor to use for pharmacokinetic studies in the obese? Br J Clin Pharmacol 58:119–133CrossRef Gren B, Duffull SB (2004) What is the best size descriptor to use for pharmacokinetic studies in the obese? Br J Clin Pharmacol 58:119–133CrossRef
13.
go back to reference Gibbs JP, Gooley T, Corneau B, Murray G, Stewart P, Appelbaum F et al (1999) The impact of obesity and disease on busulfan oral clearance in adults. Blood 93:4436–4440PubMed Gibbs JP, Gooley T, Corneau B, Murray G, Stewart P, Appelbaum F et al (1999) The impact of obesity and disease on busulfan oral clearance in adults. Blood 93:4436–4440PubMed
14.
go back to reference Topcuoglu P, Soydan EA, Ekiz F, Ayyildiz E, Dalva K, Ozcan M et al (2007) How to calculate the quantity of CD34+ cells infused? A single centre cohort study based on actual, ideal or adjusted ideal body weight. Transf Apher Sci 36:275–280CrossRef Topcuoglu P, Soydan EA, Ekiz F, Ayyildiz E, Dalva K, Ozcan M et al (2007) How to calculate the quantity of CD34+ cells infused? A single centre cohort study based on actual, ideal or adjusted ideal body weight. Transf Apher Sci 36:275–280CrossRef
15.
go back to reference Devine BJ (1974) Gentamicin therapy. Drug Intel Clin Phar 8:650–655 Devine BJ (1974) Gentamicin therapy. Drug Intel Clin Phar 8:650–655
16.
go back to reference Trickett AE, Smith S, Kwan YL (2001) Accurate calculation of blood volume to be processed by aphaeresis to achieve target CD34+ cell numbers of PBPC transplantation. Cytotherapy 3:5–10PubMedCrossRef Trickett AE, Smith S, Kwan YL (2001) Accurate calculation of blood volume to be processed by aphaeresis to achieve target CD34+ cell numbers of PBPC transplantation. Cytotherapy 3:5–10PubMedCrossRef
17.
go back to reference Sutherland DR, Anderson L, Keeney M, Nayar R, Chin-Yee I (1996) The ISHAGE guidelines for CD34+ cell determination by flow cytometry. J Hematother 5:213–226PubMedCrossRef Sutherland DR, Anderson L, Keeney M, Nayar R, Chin-Yee I (1996) The ISHAGE guidelines for CD34+ cell determination by flow cytometry. J Hematother 5:213–226PubMedCrossRef
18.
go back to reference Singh V, Krishnamurthy J, Duffey S, Meagher R, Villa M, Monreal J et al (2009) Actual or ideal body weight to calculate CD34+ cell dose in patients undergoing autologous hematopoietic SCT for myeloma? Bone Marrow Transplant 43:301–305PubMedCrossRef Singh V, Krishnamurthy J, Duffey S, Meagher R, Villa M, Monreal J et al (2009) Actual or ideal body weight to calculate CD34+ cell dose in patients undergoing autologous hematopoietic SCT for myeloma? Bone Marrow Transplant 43:301–305PubMedCrossRef
19.
go back to reference Maclean PS, Parker AN, McQuaker IG, Clark AD, Farrell E, Douglas KW (2007) Ideal body weight correlates better with engraftment after PBSC autograft then actual body weight, but is under-estimated in myeloma patients possibly due to disease-related height loss. Bone Marrow Transplant 40:665–669PubMedCrossRef Maclean PS, Parker AN, McQuaker IG, Clark AD, Farrell E, Douglas KW (2007) Ideal body weight correlates better with engraftment after PBSC autograft then actual body weight, but is under-estimated in myeloma patients possibly due to disease-related height loss. Bone Marrow Transplant 40:665–669PubMedCrossRef
20.
go back to reference Stroncek DF, Fautsch SK, Lasky LC, Hurd DD, Ramsay MK, McCullough J (1991) Adverse reactions in patients transfused with cryopreserved marrow. Transfusion 31:521–526PubMedCrossRef Stroncek DF, Fautsch SK, Lasky LC, Hurd DD, Ramsay MK, McCullough J (1991) Adverse reactions in patients transfused with cryopreserved marrow. Transfusion 31:521–526PubMedCrossRef
21.
go back to reference Zambelli A, Poggi G, Da Prada G, Pedrazzoli P, Cuomo A, Miotti D (1998) Clinical toxicity of cryopreserved circulating progenitor cells infusion. Anticancer Res 18(6B):4705–4708PubMed Zambelli A, Poggi G, Da Prada G, Pedrazzoli P, Cuomo A, Miotti D (1998) Clinical toxicity of cryopreserved circulating progenitor cells infusion. Anticancer Res 18(6B):4705–4708PubMed
22.
go back to reference Donmez A, Tombuloglu M, Gungor A, Soyer N, Saydam G, Cagirgan S (2007) Clinical side effects during peripheral blood progenitor cell infusion. Transfus Apher Sci 36:95–101PubMedCrossRef Donmez A, Tombuloglu M, Gungor A, Soyer N, Saydam G, Cagirgan S (2007) Clinical side effects during peripheral blood progenitor cell infusion. Transfus Apher Sci 36:95–101PubMedCrossRef
23.
go back to reference Ungerstedt JS, Waltz E, Uttervall K, Johansson B-M, Wahlin BE, Nassman P et al (2011) Autologous hematopoietic stem cell transplantation in multiple myeloma and lymphoma: an analysis of factors influencing stem cell collection and haematological recovery. Med Oncol. doi:10.1007/s12032-011-0029-3 Ungerstedt JS, Waltz E, Uttervall K, Johansson B-M, Wahlin BE, Nassman P et al (2011) Autologous hematopoietic stem cell transplantation in multiple myeloma and lymphoma: an analysis of factors influencing stem cell collection and haematological recovery. Med Oncol. doi:10.​1007/​s12032-011-0029-3
Metadata
Title
The use of adjusted ideal body weight for overweight patients undergoing HPC mobilisation for autologous transplantation
Authors
C. Hicks
A. Trickett
Y. L. Kwan
S. Ramanathan
Publication date
01-11-2012
Publisher
Springer-Verlag
Published in
Annals of Hematology / Issue 11/2012
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-012-1523-1

Other articles of this Issue 11/2012

Annals of Hematology 11/2012 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.